Publications by authors named "L Ehrlich"
Hospitalized COVID-19 patients exhibit diverse immune responses during acute infection, which are associated with a wide range of clinical outcomes. However, understanding these immune heterogeneities and their links to various clinical complications, especially long COVID, remains a challenge. In this study, we performed unsupervised subtyping of longitudinal multi-omics immunophenotyping in over 1,000 hospitalized patients, identifying two critical subtypes linked to mortality or mechanical ventilation with prolonged hospital stay and three severe subtypes associated with timely acute recovery.
View Article and Find Full Text PDFArticle Synopsis
- Chronic viral infections can reactivate during acute illnesses, and this study looked at how SARS-CoV-2 infection affects latent viruses like Epstein-Barr Virus (EBV) and cytomegalovirus (CMV) in over 1,154 hospitalized COVID-19 patients.* -
- The analysis showed significant reactivation of multiple virus families during the acute stage of COVID-19, which correlated with disease severity, demographics, and clinical outcomes, including higher mortality rates.* -
- Additionally, persistent viral reactivation after recovery was linked to ongoing symptoms of Post-Acute Sequelae of COVID-19 (PASC), emphasizing the importance of understanding these interactions for better treatment and management strategies.*
Article Synopsis
- The study investigates the effectiveness of enoxaparin, a medication for preventing blood clots, in critically ill children, focusing on differences in response based on age, particularly between older children and infants.
- It consists of two simultaneous clinical trials: one for older children aged 1-17 years, and another for infants under 1 year, with specific dosing protocols for each group.
- The trials are set in multiple pediatric intensive care units across the U.S., using methods like randomization, ultrasonography, and blood analysis to assess outcomes and monitor safety.
Myeloid blast-phase chronic myeloid leukemia (MBP-CML) is a rare disease with a dismal prognosis. It is twice as common as lymphoid blast-phase CML, and its prognosis is poorer. Despite the success with tyrosine kinase inhibitors in the treatment of chronic-phase CML, the same does not hold true for MBP-CML.
View Article and Find Full Text PDFCurrent intensified chemotherapy regimens have significantly increased survival rates for pediatric patients with T-cell acute lymphoblastic leukemia (T-ALL), but these treatments can result in serious adverse effects; furthermore, patients who are resistant to chemotherapy or who relapse have inferior outcomes, together highlighting the need for improved therapeutic strategies. Despite recent advances in stratifying T-ALL into molecular subtypes with distinct driver mutations, efforts to target the tumor-intrinsic genomic alterations critical for T-ALL progression have yet to translate into more effective and less toxic therapies. Ample evidence now indicates that extrinsic factors in the leukemic microenvironment are critical for T-ALL growth, infiltration, and therapeutic resistance.
View Article and Find Full Text PDF